Form 4: IRIX Insider Purchases 1,000 Shares at ~$1.28
Rhea-AI Filing Summary
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 08/27/2025. The filing shows three open-market acquisitions totaling 1,000 shares: 500 shares at $1.28, 250 shares at $1.2746, and 250 shares at $1.2964. Each line reports the resulting beneficial ownership rising sequentially to 50,245; 50,495; and 50,745 shares, and ownership is reported as direct. No derivative transactions were reported. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Transparent disclosure of three open-market purchases with exact share counts and prices
- Direct ownership reported, ending at 50,745 shares, clarifying insider stake
- No derivatives reported, simplifying assessment of insider exposure
Negative
- None.
Insights
TL;DR: Insider purchased 1,000 IRIX shares in small separate trades, increasing direct holdings to 50,745 shares.
The reported transactions are routine open-market purchases by the company's CFO totaling 1,000 shares executed on 08/27/2025 at prices between $1.2746 and $1.2964. The filing lists incremental beneficial ownership amounts after each trade, ending at 50,745 shares held directly. There are no derivative instruments disclosed and no amendments noted. From a financial analysis perspective, these are small, transparent purchases recorded under Section 16 reporting rules and provide limited new information about company operations or financial performance.
TL;DR: Form 4 properly discloses direct insider purchases and is signed by an authorized attorney-in-fact.
The Form 4 identifies the reporting person, relationship as Chief Financial Officer, and discloses three purchase transactions on 08/27/2025 with exact share counts and prices, satisfying disclosure requirements. Ownership is explicitly listed as direct. The signature block shows the form was executed by an attorney-in-fact, which is permitted when properly authorized. There are no indications of Rule 10b5-1 plan use or derivative activity. Compliance-wise, the filing appears complete for the disclosed transactions.